Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Chiara De PhilippisIRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy.ORCID 0000-0002-7738-997X
Cristina ZucchinettiIRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy.
Daniele ManninaIRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy.
Mauro KramperaHematology and Bone Marrow Transplant Unit, Department of Engineering for Innovative Medicine, Section of Biomedicine of Innovation, University of Verona, Verona, Italy.
Pier Luigi ZinzaniIRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy.ORCID 0000-0002-2112-2651
Annalisa ChiappellaDivision of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.ORCID 0000-0002-2977-0098
Alice di RoccoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Maria Chiara TisiHematology Unit, San Bortolo Hospital, AULSS 8 Berica, Vicenza, Italy.
Flavio PistoleseIRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy.
Laura GiordanoIRCCS Humanitas Research Hospital- Humanitas Cancer Center, Biostatistic Unit, Rozzano, Milan, Italy.
Armando SantoroIRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy. armando.santoro@humanitas.it.
Stefania BramantiIRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy.ORCID 0000-0002-4117-7991
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellStandard of CareReceptors, Antigen, T-Celltisagenlecleucel
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma. · full record | OpenQuestion